Cargando…

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis

BACKGROUND: In multiple sclerosis, impact of treatment on disability progression can be confounded if treatment also reduces relapses. OBJECTIVE: To distinguish siponimod’s direct effects on disability progression from those on relapses in the EXPAND phase 3 trial. METHODS: Three estimands, one base...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cree, Bruce AC, Magnusson, Baldur, Rouyrre, Nicolas, Fox, Robert J, Giovannoni, Gavin, Vermersch, Patrick, Bar-Or, Amit, Gold, Ralf, Piani Meier, Daniela, Karlsson, Göril, Tomic, Davorka, Wolf, Christian, Dahlke, Frank, Kappos, Ludwig
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414818/ https://www.ncbi.nlm.nih.gov/pubmed/33205682 http://dx.doi.org/10.1177/1352458520971819

Ejemplares similares

Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study
por: Gold, Ralf, et al.
Publicado: (2022)

Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years
por: Cree, Bruce AC, et al.
Publicado: (2022)

Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial
por: Arnold, Douglas L, et al.
Publicado: (2022)

Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2021)

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Learning ability correlates with brain atrophy and disability progression in RRMS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

White matter lesion location correlates with disability in relapsing multiple sclerosis
por: Gaetano, Laura, et al.
Publicado: (2020)

Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?
por: Bigaud, Marc, et al.
Publicado: (2023)

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
por: Gold, Ralf, et al.
Publicado: (2013)

A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm
por: Tolley, Chloe, et al.
Publicado: (2020)

Prospects of siponimod in secondary progressive multiple sclerosis
por: McGinley, Marisa, et al.
Publicado: (2018)

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
por: Leppert, David, et al.
Publicado: (2022)

No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis
por: Nixon, Richard, et al.
Publicado: (2014)

Siponimod for multiple sclerosis
Publicado: (2021)

A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
por: Kuhle, Jens, et al.
Publicado: (2019)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
por: Hauser, Stephen L., et al.
Publicado: (2023)

The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis
por: Cohan, Stanley L., et al.
Publicado: (2022)

COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series
por: Sullivan, Roseanne, et al.
Publicado: (2021)

Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE
por: Gold, Ralf, et al.
Publicado: (2020)

Siponimod ameliorates experimental autoimmune neuritis
por: Uchi, Takafumi, et al.
Publicado: (2023)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
por: Vališ, Martin, et al.
Publicado: (2023)

Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies
por: Havrdova, E., et al.
Publicado: (2017)

Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results
por: Gold, Ralf, et al.
Publicado: (2021)

“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2017)

Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
por: Behrangi, Newshan, et al.
Publicado: (2019)

Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2020)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Does Siponimod Exert Direct Effects in the Central Nervous System?
por: Kipp, Markus
Publicado: (2020)

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2021)

Migraine, interferon β1a and siponimod immunomodulator therapies
por: Dahaba, Ashraf A., et al.
Publicado: (2022)

Siponimod Modulates the Reaction of Microglial Cells to Pro-Inflammatory Stimulation
por: Gruchot, Joel, et al.
Publicado: (2022)

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
por: Kappos, Ludwig, et al.
Publicado: (2020)

α4-integrin receptor desaturation and disease activity return after natalizumab cessation
por: Derfuss, Tobias, et al.
Publicado: (2017)

Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
por: Gentile, Antonietta, et al.
Publicado: (2016)

Impact of siponimod on vaccination response in a randomized, placebo-controlled study
por: Ufer, Mike, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_t5lp1abph621vtssa80lfiv4b9